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Abstract
High resolution, system-wide characterizations have demonstrated the capacity to identify genomic regions that undergo
genomic aberrations. Such research efforts often aim at associating these regions with disease etiology and outcome.
Identifying the corresponding biologic processes that are responsible for disease and its outcome remains challenging.
Using novel analytic methods that utilize the structure of biologic networks, we are able to identify the specific networks
that are highly significantly, nonrandomly altered by regions of copy number amplification observed in a systems-wide
analysis. We demonstrate this method in breast cancer, where the state of a subset of the pathways identified through these
regions is shown to be highly associated with disease survival and recurrence.
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Introduction
Biologic phenotypes emerge as a consequence of genes
interacting through complex networks. Oncogenesis has been
shown to be dependent on biologic networks that control processes
such as apoptosis, senescence, proliferation, and angiogenesis
[1,2]. However, it is clear that current knowledge of which
processes influence diverse cancer phenotypes is incomplete. This
is especially true when it comes to understanding processes
associated with disease outcome.
A complex collection of genomic alterations occur during tumor
cell evolution, including mutations, translocations, and copy
number alterations. For example, genome-wide analysis of breast
tumors by numerous techniques have reproducibly demonstrated
recurrent patterns of copy number alteration (CNA)
[3,4,5,6,7,8,9,10,11]. The expression of genes within these altered
segments has been demonstrated to be correlated with the copy
number state of the region [3,9,12,13,14,15,16,17,18,19]. How-
ever, it is unclear whether these recurrent patterns represent the
most important set of CNAs or represent only a subset of key
regions.
Patterns of copy number alteration have proven valuable in
classification of cancer subtypes and can serve as predictors of
patient outcome [19]. These alterations target genes that influence
networks that provide the tumors with a selective advantage over
cells of normal composition. Given their association with outcome,
it is likely they also influence processes that drive clinical
phenotypes and response to interventions.
Identifying the processes targeted by the regions identified
through system-wide analysis is complex. For example, copy
number-altered regions contain large numbers of genes. There is
also a tremendous degree of between-individual heterogeneity in
the inventory of regions found to be altered.
Work by others to identify processes underpinning complex
traits has combined inherited variants and network analysis to map
multifactorial, heterogeneous disease phenotypes [20]. In this
work, the authors extend traditional gene mapping approaches by
including putative gene interactions to address heterogeneity.
Others have examined multidimensional data sets that include
different genome-scale measurements simultaneously in the
context of pathways [21,22,23].. They apply statistical method
to measure pathway enrichment and use gene-expression data to
assess variation of pathway activity. Through such analyses they
hypothesize new cell functions.
In the work presented here, we compliment and extend these
approaches to systematically analyze somatic CNAs to identify
biologic networks underpinning cancer phenotypes. We demon-
strate the method using the breast cancer data set of Chin et al
[24]. We identify altered pathways differentially targeted by copy
number aberrations.
Similar to previous approaches, we addresse the heterogeneity
of patterns by recognizing that differing patterns of CNA may
represent alternative routes that cancer cells may take to alter the
same core set of common biologic processes. The apparent
heterogeneity in map location associated with CNAs may simply
reflect the fact that the genes comprising a given network are
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1distributed throughout the genome. We therefore test whether
individual canonical pathways are non-randomly targeted across
copy number change regions. In contrast to previous approaches,
we leverage existing network structure as opposed to de novo
creating networks. The network interaction structure for these
canonical networks is then leveraged for mapping phenotypes. We
utilize previously described methods [25] to determine whether
altered state of non-randomly altered processes can predict patient
outcome.
Results
Chin et al. have previously reported genome-wide copy number
and gene expression analysis of 145 primary breast cancer tumors
[19]. These alterations were determined using genome BAC array
CGH [26,27,28,29] comprised of 2464 BACs selected at
approximately mega base intervals along the genome as described
previously [26,28]. Utilizing this data set and the process described
in Materials and Methods, the gene content of each segment
described in Chin et al. was identified.
Canonical biologic network structure information and gene
content was obtained from public sources [30,31,32].A total of 565
canonical pathways were examined. These pathways represent
collections of interactions that are subsets of larger biologic
networks curated to capture specific functions. Therefore, their
gene content is not unique. The gene content of these pathways
ranges dramatically. For example, as the pathway ‘‘degradation of
the RAR and RXR by the proteasome [33]) contains only 2 genes
while IL12 Signaling Pathway’’ [34,35,36])contains 80.
To account for heterogeneity of gene involvement when analysis
is performed using a network model we define a new statistical
metric (described in equations (2.5) and (2.6) in Materials and
Methods). Significance for each pathway across samples was
assessed using the Fisher’s Omnibus [49] and adjusted for multiple
comparisons using the Bonferoni method.
Applying the methods to the data provided by Chin et al., we
identify pathways in which the genes altered by CNAs are highly
significantly over-represented when compared to random expec-
tations (Table S1).
To illustrate the diverse over-representation patterns for a given
network we present the CNA events associated with the pathway
‘‘CDC25 and CHK1’’ [37] (Figure 1). In the figure, gene
amplification is denoted through a purple square and gene
deletion through black squares.
As Figure 1 demonstrates, no single gene within the pathway
appears to be the differential target of CNA across the 18 breast
cancer samples shown… or when examined across the remaining
127 individuals in the study.
On the other hand, we can see that the pathway, as a unit, is
targeted in almost every subject in the panel (the entire panel of
subjects for this pathway is included in Table S2). Note, the metric
(see Materials and Methods) compensates for pathway size.
As such, to obtain a significant p-value, larger pathways need to
accumulate a larger number of gene amplifications or deletions.
We next assessed whether the networks identified by over-
representation of CNA are associated with disease outcome. Using
pathway activity and pathway consistency scores [26], we clustered
the individuals according to their pathway metrics and performed
survival analysis. When we stratify the patients to two groups, we
can draw the survival curves and check to see if they separate the
population in a significant manner (Figure 2).
Iterating over the collection of hundreds of pathways, we find 29
pathways that meet significance criteria of p,0.05 (Table S3).
However when adjusting for multiple testing using the Bonferroni
method only two pathways significantly targeted by genomic
alterations are also highly associated with survival;’’‘‘Hypoxic and
oxygen homeostasis regulation of HIF-1-alpha’’ [38,39,40], and
Glycosaminoglycan degradation [refs].
An alternative approach to adjusting for multiple comparisons
for assessing significance is to validate findings those pathways that
show marginal significance across data sets. Two public data sets
with expression data and disease outcome were selected from the
Gene Expression Omnibus database (http://www.ncbi.nlm.nih.
gov/geo) [41] The first data set (GSE2990) [42] contained 189
individuals. The second (GSE3494) [43] contained 251 individ-
uals. Gene expression in both datasets utilized the Affymetrix
platform for determining gene expression state. Of the original 29
pathways observed to be significantly associated with survival in
Chin et al. [19], 8 were observed to be significant in GSE2990 and
8 were observed to be significant in GSE3494. A total of 4
pathways were observed to be significant in all three data sets.
Concordance among the datasets is more than would be expected
by chance alone.
Discussion
The above results suggest that genes in CNA non-randomly
target processes important for oncogenic state. In the work
Figure 1. Copy Number alterations in 18 subjects in the ‘‘CDC25 and CHK1’’ pathway. Purple rectangles signify gene amplification and
black squares signify deletion. Each column represents a randomly chosen subject with a total of 18 subjects. Each row represents a different gene of
the pathway genes. Different subjects target the ‘‘CDC25 and CHK1’’ pathway through alternating genomic strategies. The pathway as a unit,
however, is targeted throughout the population.
doi:10.1371/journal.pone.0014437.g001
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biologic processes that may be the target of these alterations.
Moreover, the pathways over-represented in these segments show
differences in activity and consistency that is related to cancer
outcome.
The total number of pathways identified as non-randomly
targeted is striking. One possible explanation is the lack of
independence of the gene content associated with each pathway.
Hierarchical clustering of the pathways utilizing the p-value
associated with the non-random targeting (Table S4) confirms that
pathways with related names commonly cluster with high
correlation (r.0.5, data not shown). Inspection of the pathway p-
values across individuals shows tremendous variability (Table S4).
This suggests diverse underlying molecular mechanisms driving
oncogenesis. Unfortunately, no obvious pattern of clustering of
individuals emerges from analysis of pathway-specific variability.
CNA have been previously demonstrated to show association
with patient outcome [44,45,46,47]). In the Chin et al. [19]
individual copy number altered segments showed association with
survival and disease recurrence, but performed unevenly. When
taken as a set, they found that alteration of any of what they
identified as ‘‘recurrent amplicons’’ was associated with reduced
survival duration (p,0.04) and distant recurrence (p,0.01).
The results obtained from pathway-based analysis of the same
data set produce a striking improvement and suggest that
pathways may represent a better way to evaluate recurrent
alterations. Two pathways show a highly significant association
within Chin et al. alone and 4 pathways show significance across
multiple data expression datasets. Because of the high dimension-
ality of systems-wide data, there is always a danger of over fitting.
As such, results from an individual study should be viewed
skeptically. However, the significant concordance across multiple
provides independent validation.
The increased reproducibility and magnitude of the effect
associated with pathway state compared with that observed in the
direct examination of ‘‘recurrent’’ regions may be attributable to
several factors. At a mechanical level, examination of data at the
pathway level permits the information from different regions to be
integrated across the network. The fact that any given recurrent
region is amplified is no longer the critical predictor. What
emerges instead is the importance of sets of altered regions whose
individual members hit different parts of a targeted pathway.
Pathways pre-aggregate the effects of multiple genes. As such, it is
possible to detect multigene interactions that influence cancer
phenotypes but which, if not aggregated in a pathway, might fail to
meet the test of statistical significance in a small dataset.
CNA is only one factor that could be driving pathway
involvement in phenotypes. Many other genomic mechanisms
(e.g. individual gene mutations, epigenetic activation/silencing)
can influence the state of the pathway. As such, the pathways
identified here represent a subset of those likely involved.
Conceptually, it is likely that because the pathway is the
underlying unit of the phenotype, focusing on pathways increases
signal and reduces noise. Genomic alterations that accumulate
during oncogenesis and disease progression occur at random. The
observed coherence likely arises because certain processes must be
altered to arrive at the given phenotype. Apparent genomic
heterogeneity, ‘‘noise’’, arises because there are multiple ways a
pathway can be changed. All of these ways are ‘‘signal’’ from the
perspective of a pathway.
Figure 2. Kaplan-Meier survival curve of the ‘‘CDC25 and CHK1’’ pathway (P-value=0.04). This pathway, which has been highlighted
through its highly significant p-value as targeted by genomic alterations, is highly significant in its ability to stratify patients’ prognosis. The figure
demonstrates how significant genomic alterations indicate a pathway’s significance as a stratification tool.
doi:10.1371/journal.pone.0014437.g002
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for copy number alteration to pathway (above) may prove useful
for other genome analyses such as genome-wide mutational
screens or association studies. For example, the complex
mutational patterns seen in the 1672 genes characterized in
human and breast cancer [48] are all observed to mutate genes in
one or more of 6 canonical pathways state identified from gene
expression data which universally differentiates tumor from
normal [25]. Similarly, complex, low odd-ratios haplotype
associations patterns may reflect heterogeneous routes to alter
common pathways. The above observations have several practical
implications in considering next-generation intervention strategies.
First, the networks provide a basis for designing combinatorial
therapies. Examination of the networks, and their activity states,
provides a rational means of determining which combination of
genes need to be targeted in order to alter the state of critical
nodes. It is also interesting that not all alterations in pathways
states influence outcome. This observed difference in effect on
outcome, which may reflect the result of natural experiments by
the tumor, may also prove important in prioritizing which genes
and interactions might be most productively targeted to improve
outcome.
Materials and Methods
Mapping Entrez Gene to Golden Path
NCBI’s Entrez Gene database contains 36470 human records,
25441 of them annotated as protein-coding. For each gene in this
set we used a variety of methods to find its location Golden Path
genome sequence. Version (hg18) of the genome database contains
extensive annotations which we used wherever possible. In some
cases we used BLAT to find genomic locations.
The positions of approximately 18,342 (,54%) genes were
annotated directly in Golden Path’s refLink and refGene tables.
While this is the most straightforward reference, it leaves 18,128
genes unmapped, 6,757 (,18.5%) of them protein-coding.
In cases where a direct gene annotation was not available, we
searched Golden Path’s annotations for the locations of associated
sequences from a variety of sources, listed below in order of
preference:
– mRNA accessions from Entrez Gene’s ‘‘gene2accession’’ table
– cross-referenced accessions from the HUGO database
– cross-referenced accessions from the uniSTS database
– primary representative sequence from associated UniGene
cluster
– mRNA sequences from associated UniGene cluster
– EST sequences from associated UniGene cluster
Accessions were gathered from each of these sources in turn,
and then looked up in various Golden Path annotation tables
(all_mrna, stsMap, clonePos, and all_est). A locally-built database
of mRNA and refseq BLAT results (assembled by Robert Clifford)
was also searched, providing some additional matches. The
resulting genomic locations of the search sequences were
aggregated, and accepted as the gene’s position if the locations
fell within a 3 mb region (3 mb being a somewhat arbitrary cutoff
based on the largest observed refLink-based gene mapping of
approximately 2.3 mb). If a chromosome annotation was available
from Entrez Gene, HUGO, or uniSTS, genomic positions were
only included if they were on the same chromosome. A known
chromosome annotation was required in the case of UniGene
mRNA and EST sequence lookups.
In cases where accession annotations were available but the
positions were not found, we performed our own BLAT searches.
This was necessary for certain classes of accessions which do not
appear in the Golden Path database (e.g. the ‘‘XM_’’ series of
predicted refseqs). If a chromosome annotation was available for
the gene, a BLAT search was run only against that chromosome,
otherwise all chromosomes were searched. Results were aggre-
gated and accepted as the gene’s position if they fell within a
10 mb or smaller region. This is a less strict requirement than
used in the accession-based mapping system, yet it can provide at
least a general position, much more specific than a cytogenetic-
based coordinate (the only mapping information available for
some Entrez Gene entries). If plausible matches were found on
multiple chromosomes, the gene mapping was rejected as
ambiguous.
BLAT results are annotated with one of four categories of
match types, so the annotations may be excluded later if they are
considered too broad. The four categories are:
1. A single perfect match for the query sequence was found.
The ideal mapping result.
2. More than one perfect match for the query sequence was
found.
3. A single near-perfect match (at least 95% but less than 100%
identity) was found.
4. Multiple near-perfect matches were found.
Preferential treatment was given to perfect refseq matches in the
results – i.e. a perfect BLAT match to a refseq was considered the
gene’s genomic position, regardless of the presence of other near-
perfect matches in the results.
If mapping failed by any of the above methods a few crude
methods of last resort were attempted:
1. if a gene was positioned on an NCBI genomic contig
sequence(NC_* series accession, via EG’s ‘‘gene2refseq’’ table),
and a neighboring gene on the same chromosome, arm,
and band could be found in Golden Path, the relative
distance between the two genes in the NCBI sequence
was applied to the Golden Path coordinates to
approximate
its position.
2. If a gene had only a cytogenetic location available, coordinates
of Golden Path-mapped genes with the same cytogenetic
location were aggregated and a union of their position
generated. The resulting mappings are extremely broad but
at least point to a general molecular region which may still be
useful in some circumstances.
Mapping BACs to Golden Path
The second dataset to be mapped to Golden Path consisted of
the set of BACs used in the CGH arrays from Chin et al [24]. As
with the Entrez Gene mapping process, the Golden Path
annotation database contains an ideal table for our purposes,
‘‘bacEndPairs’’, holding the genomic positions of BACs whose end
sequences have both been mapped. However, only approximately
39% of the BACs in our set contain an entry in this table. The
‘‘fishClones’’ table provided mappings for an additional 6% of the
BACs. For the remainder we used BAC-related annotations as a
basis for mapping.
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annotations. From it, we extracted BAC-related accession, end
sequence, STS and chromosome information. The registry also
provided cross-connections to uniSTS, from which we gathered
additional related accessions. We searched for the resulting
sequences in Golden Path’s all_mrna, clonePos, stsMap, and
all_ests tables. We also took special note of any matches for BAC
end sequences. In addition to the clone registry, we also used
annotations from the UCSF 2.0 arrays (data from http://cancer.
ucsf.edu/array/analysis/), as well as GenBank records referencing
BAC names in the title block. Genome mappings were accepted
for the BACs if they were no longer than 500 kb in length, and
mappings to ambiguous chromosomes were rejected.
For BACs which could not be found using NCBI clone registry
or UCSF array annotations, we attempted a surrogate-based
mapping approach. Chin et als [1] CGH array annotations
provided rough genomic positions (in megabases) whose coordi-
nates aligned most closely with an older genome build, hg16. For
each BAC, we extracted sequence IDs from hg16 which were
annotated as being near this position. Sets of sequences were
extracted from each of the all_mrna, stsMap, and all_est
annotation tables. For mRNAs and STSs, we used sequences
located within plus or minus 5 kb of the target location. For ESTs,
we took sequences within plus or minus 1 kb of the target position.
These extracted sequences were used as surrogates for the BACs,
and looked up in hg18, searching (in order of preference) mRNAs,
STSs, and ESTs. This approach was used to generate hg18
positions for approximately 8.7% of the BACs.
For BACs that could not be mapped to hg18 using any of the
above methods, a second pass was performed to find generate
approximate positions based on interpolated neighboring BAC
locations. For each BAC, we tried to find flanking BACs with hg18
mappings. We then applied relative offsets to the hg18 positions
based on the spacings in the hg16 positions. This was only
required for approximately 1.4% of the BACs.
BAC preprocessing. Two sets of modified genomic positions
are generated for each BAC, which we refer to as expanded and
extended coordinates.
Expanded coordinates are an attempt to compensate for the
many cases where BAC mapping and end-sequence information is
incomplete. They are intended to ensure that all BACs cover a
minimum amount of the genome, and that fully-mapped BACs do
not crowd out BACs having less complete mapping annotations.
This involves expanding mapped BAC coordinates up to
approximately 165kb, which is our observation of the median
size of BACs where both end sequences have been mapped.
Coordinates are not expanded in cases where both end sequences
have been mapped, or if existing mapping information spans
100kb or more. If a single end sequence mapping is known, the
expansion is made away from the anchored end, otherwise the
coordinates are expanded equally in either direction. Collisions
during expansion between closely-mapped BACs are detected and
resolved by a multi-pass process where the available intervening
space is assigned equally between BACs. If expansion in one
direction causes a collision with a neighboring BAC, appropriate
compensatory expansion is attempted in the other direction, unless
that end is fixed by the presence of a known end sequence.
Extended coordinates build upon the expanded mappings by
dividing unassigned regions of the genome between neighboring
BACs. This provides pseudo-tiling coverage of the genome,
allowing any given region to be associated with the most
appropriate BAC in the set. Generating extended coordinates
requires expanded coordinates to be calculated first, to allow the
most equitable assignment of intervening regions.
Expanded and extended coordinates are computed dynamically
based on the BAC membership of the CGH array being worked
with. While the hg16-based CGH arrays were intended to sample
the genome at regular intervals, their computed positions in hg18
are not as neatly spaced. For these purposes the BACs were
arranged as we observed them in hg18.
There are cases where BAC coordinates overlap. In cases where
a BAC is computed to lie entirely within a larger BAC, the smaller
BAC receives the same final coordinates as the larger BAC (it is
essentially considered a duplicate). In cases where a BAC partially
overlaps with another, the coordinates in the overlap region are
left unchanged, and no expansion or extension is performed on the
end with the overlap.
Associating BACs with genes
There are three basic types of intersections between gene and
BAC coordinates:
1. The gene’s mapping falls entirely within the BAC’s mapping.
2. The gene’s mapping lies partly within the BAC’s mapping and
partly outside.
3. The gene’s mapping is larger than the BAC’s mapping.
This can happen for genes with very broad cytogenetically-
derived gene mappings.
Gene-to-BAC associations of the first type are trivial to calculate.
The latter two cases require some additional steps to determine
whether a gene should be associated with a BAC or not.
Associations are generally rejected if the length of the BAC
mapping is less than one-third the length of the gene mapping.
This prevents associations from being formed based on insubstan-
tial overlaps. If the extended set of BAC coordinates is being used,
an association is rejected unless at least 50% of the gene’s
coordinates lie within the BAC’s coordinates. Since in extended
mode BACs tile the genome completely, this step ensures that
genes in border regions will be assigned to one BAC exclusively.
Specific associations of BACs and their genes has been previously
described in Chin et al. [24].
Identifying Genes in Copy Number Altered Regions. In order
to identify the genes in the copy number altered regions it was
necessary to translating BACs coordinate used in the comparative
genomic hybridization (CGH) assays into genome coordinates.
This involved mapping the Entrez Gene database and the CGH
BACs to a common coordinate space (Golden Path human
genome build hg18), and then overlaying the results. These
processes are described in the supplemental material [19].
Mapping Genes to Pathways
We determined the list of genes used in each pathway in by
query of the Pathway Interaction Database [49].
p-value for a pathway’s genomic alterations in a specific
sample
Each pathway network has been taken as a set of genes. That is,
for each pathway, and according to (2.4), we listed the genes which
are members of the pathway.
To determine the probability that a pathway is to be hit by
exactly k hits, we first calculate the probability that the pathway is
randomly hit 0,1,...,k times. With G genes quantified in a given
platform (for example, a platform that covers the entire genome
will cover roughly G=24,000), and Ni genes in a pathway i (Ni is
usually between 10–70 genes) we get:
Cancer Networks Alterations
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Ni~number of genes in pathway i
Mi~total number of altered genes in sample j
ki,j~number of genes altered in pathway i in sample j
ð2:4Þ
The probability of randomly hitting zero to ki,j genes, given that Mj
genes are altered in sample jis the hypergeometric cumulative
distribution function:
Pi,j~
X
ki,j
q~0
Mj
q
  
G{Mj
Ni{q
  
G
Ni
   ð2:5Þ
The associated p-value is therefore defined as:
P-value of pathway i in sample j~pvali,j~1{pi,j ð2:6Þ
p-value for a global pathway targeting across a
population
To be able to statistically quantify genomic targeting of a
pathway across a population of subjects we need to iterate across
the p-values defined in (2.5). This is in effect a combination of one
sided binomial tests. This has been solved by different techniques,
including Fisher’s Omnibus [50], which we are using here. This
test statistics for pathway i is expressed here as:
Fi~{2
X
jlog(pvali,j) ð2:7Þ
and the corresponding p-value is:
P-value for pathway i across population~pvali~1{x2 Fi,2d ðÞ
ð2:8Þ
where x2 is the Chi-square cumulative distribution function and d
are the number of degrees of freedom (number of samples).
Supporting Information
Table S1 Bonferroni correction was applied on the p-values
calculated using the Fisher Omnibus test in order to address the
problem of multiple comparisons. The value for significance was
assign to be 8.834610
25, which is 0.05/566 (when 566 is the
number of pathways). Table S1 shows all 566 pathways calculated
from Chin’s dataset with the p-value calculated via Fisher
Omnibus test. In addition, every p-value was adjusted and
pathway significance was reassigned.
Found at: doi:10.1371/journal.pone.0014437.s001 (0.65 MB
DOC)
Table S2 Table S2 shows the entire panel of subjects for the
following pathway ‘‘cdc25 and chk1 regulatory pathway in
response to DNA damage’’. This pathway is composed of 9 genes.
This table shows the copy number alterations across 145 breast
cancer patient: 21 indicates deletion, 1 indicates amplification and
0 indicates of no significant change.
Found at: doi:10.1371/journal.pone.0014437.s002 (0.19 MB
DOC)
Table S3 Table S3, presented here, shows all pathways that
found to be significant using Kaplan-Meier survival analysis. All of
the pathways presented here were found to be significantly
targeted through copy number alteration using the Fisher
Omnibus test (after correction). All 29 pathways were tested in
two more public datasets obtain from GEO (http://www.ncbi.
nlm.nih.gov/geo). A - activity, C - consistency.
Found at: doi:10.1371/journal.pone.0014437.s003 (0.05 MB
DOC)
Table S4 The table details the Fisher’s Omnibus value for each
pathway. Columns 3 and onward give the detailed p-value
obtained through the Hypergeometric function, as it has been
calculated per patient, per pathway.
Found at: doi:10.1371/journal.pone.0014437.s004 (1.56 MB
XLS)
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